天坛生物
(600161)
| 流通市值：385.79亿 | | | 总市值：385.79亿 |
| 流通股本：19.77亿 | | | 总股本：19.77亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,110,392,965.34 | 1,317,766,404.91 | 6,031,865,460.16 | 4,073,361,821.56 |
| 营业收入 | 3,110,392,965.34 | 1,317,766,404.91 | 6,031,865,460.16 | 4,073,361,821.56 |
| 二、营业总成本 | 2,079,476,311.38 | 908,034,937.26 | 3,517,680,781.42 | 2,397,917,802.96 |
| 营业成本 | 1,698,258,337.49 | 713,279,217.18 | 2,732,440,125.66 | 1,819,624,391.19 |
| 税金及附加 | 31,863,323 | 13,238,297.74 | 60,953,820.06 | 41,581,233.51 |
| 销售费用 | 60,356,476.12 | 34,343,579.04 | 133,389,253.72 | 119,806,910.51 |
| 管理费用 | 232,973,894.35 | 118,340,412.34 | 481,024,899.62 | 348,454,781.96 |
| 研发费用 | 56,936,180.12 | 30,297,221.48 | 142,786,644.46 | 98,702,282.76 |
| 财务费用 | -911,899.7 | -1,463,790.52 | -32,913,962.1 | -30,251,796.97 |
| 其中:利息费用 | 4,337,436.62 | 2,403,980.7 | 5,120,807.81 | 3,812,140.78 |
| 其中:利息收入 | 6,510,633.51 | 4,450,202.9 | 40,852,679.49 | 36,310,982.02 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 22,432,891.35 | 8,958,360.98 | 63,926,881.42 | 31,201,833.44 |
| 资产处置收益 | 204,679.09 | 204,679.09 | 37,503.49 | 37,503.49 |
| 资产减值损失(新) | -3,801,539.47 | -1,747,267.39 | -53,018,376.3 | -1,573,066.47 |
| 信用减值损失(新) | -33,550,584.65 | -19,718,691.93 | -7,340,604.87 | 1,805,831.58 |
| 其他收益 | 25,759,579.95 | 8,818,518.86 | 39,995,227.79 | 19,678,598.03 |
| 四、营业利润 | 1,041,961,680.23 | 406,247,067.26 | 2,557,785,310.27 | 1,726,594,718.67 |
| 加:营业外收入 | 1,845,000.68 | 292,883.21 | 1,161,597.68 | 408,972.9 |
| 减:营业外支出 | 5,436,525.64 | 261,459.89 | 11,729,405.16 | 2,570,232.55 |
| 五、利润总额 | 1,038,370,155.27 | 406,278,490.58 | 2,547,217,502.79 | 1,724,433,459.02 |
| 减:所得税费用 | 172,570,069.13 | 68,995,470.46 | 434,952,986.44 | 297,042,510.63 |
| 六、净利润 | 865,800,086.14 | 337,283,020.12 | 2,112,264,516.35 | 1,427,390,948.39 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 865,800,086.14 | 337,283,020.12 | 2,112,264,516.35 | 1,427,390,948.39 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 632,562,146.1 | 244,145,675.45 | 1,549,164,832.24 | 1,051,719,466.85 |
| 少数股东损益 | 233,237,940.04 | 93,137,344.67 | 563,099,684.11 | 375,671,481.54 |
| 扣除非经常损益后的净利润 | 618,015,305.4 | 239,155,852.86 | 1,518,650,457.88 | 1,043,625,550.66 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.32 | 0.12 | 0.78 | 0.53 |
| (二)稀释每股收益 | 0.32 | 0.12 | 0.78 | 0.53 |
| 八、其他综合收益 | - | - | 19,095,716.14 | 19,095,716.14 |
| 归属于母公司股东的其他综合收益 | - | - | 14,131,784.73 | 14,131,784.73 |
| 九、综合收益总额 | 865,800,086.14 | 337,283,020.12 | 2,131,360,232.49 | 1,446,486,664.53 |
| 归属于母公司股东的综合收益总额 | 632,562,146.1 | 244,145,675.45 | 1,563,296,616.97 | 1,065,851,251.58 |
| 归属于少数股东的综合收益总额 | 233,237,940.04 | 93,137,344.67 | 568,063,615.52 | 380,635,412.95 |
| 公告日期 | 2025-08-22 | 2025-04-26 | 2025-03-29 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |